Company intelligence / Profile preview
Innogen
Shanghai, Shanghai, Chinainogen.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Commercial
01
Overview
Innogen has achieved approval in China for its lead GLP‑1 receptor agonist, Efsubaglutide Alfa, targeting type 2 diabetes. The company’s pipeline includes additional programs addressing both type 1 and type 2 diabetes, obesity, NASH/MASH, with a strong emphasis on recombinant/fusion proteins. It recently filed for a $100 million Hong Kong IPO to support commercialization and further R&D efforts. Analysts note positive clinical progress but highlight competitive challenges in the GLP‑1 space.
- Therapeutic areas
- Metabolic DisordersEndocrinology
- Modalities
- Recombinant proteinFusion proteinSmall molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Innogen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Innogen.